CORVUS PHARMAC. DL-,0001

Corvus published in Blood the phase‑1/1b results for Soquelitinib in T‑cell lymphomas. In the 200 mg twice‑daily cohort, six complete and three partial responses were observed among 36 patients; in patients with 1–3 prior therapies, nine of 24 achieved an objective response, with median PFS of 6.2 months and median OS of 28.1 months. The agent was well tolerated up to 600 mg twice daily, showed no dose‑limiting toxicities, and via selective ITK inhibition leads to Th1 skewing; Corvus plans a phase‑3 trial in relapsed/refractory PTCL and is conducting further phase‑2 studies in atopic dermatitis and other indications. » Plus sur de.investing.com

Corvus Pharmaceuticals reported strong Phase 1 data for oral ITK inhibitor soquelitinib in atopic dermatitis with 75% EASI-75 at the highest dose versus 20% for placebo and sustained benefit after dosing stopped. The company is advancing a ~200-patient Phase 2 SEERA-1 trial with enrollment due to complete in early 2027 and results expected the following quarter, while also funding a China partner trial. Corvus ended the quarter with $215 million in cash after a $189 million raise, but R&D costs and net losses rose sharply as the company remains essentially a one-drug story. A Phase 3 lymphoma program faces a futility review in Q1 2027 and short interest remains elevated at about 24.7%, highlighting execution and clinical risk ahead. » Plus sur finance.yahoo.com

Corvus Pharmaceuticals highlights Phase 1 atopic dermatitis data for oral covalent ITK inhibitor soquelitinib showing up to 75% EASI-75 and a clean safety profile in a small cohort. The company has about $236.7 million in cash, funded into Q2 2028, and plans a Phase 2 readout in 1H 2027 that could validate competitive positioning versus Dupixent. Key risks include the small sample size of early efficacy data and uncertain long-term safety of a covalent inhibitor, while additional pipeline assets and late-stage programs provide multiple upside pathways. » Plus sur finance.yahoo.com